Rejuvenate Bio

Summary active Updated Jun 9, 2026

This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.

Location San Diego, CA
Latest Stage Series A
Total Raised $6M
Sector
biotech gene-therapy longevity animal-health

Founders

Daniel Oliver CEO & Co-Founder

About

Rejuvenate Bio is a San Diego-based biotechnology company developing gene therapies for chronic and age-related diseases 1. The company’s platform is initially being applied to companion animal health through a strategic R&D collaboration with Merck Animal Health, with longer-term ambitions to translate gene therapy approaches into treatments for age-related conditions 12.

Funding History

Date Round Amount Lead Co-investors
2026-06-08 Series A $6M VCapital Merck Animal Health, Kendall Capital Partners, Connecticut Innovations, Digitalis 12

What Investors Say

“This investment reflects our ongoing commitment to partner with leading innovators to advance new capabilities in animal health.”

— Merck Animal Health statement on Rejuvenate Bio investment 1

What Founders Say

“We believe gene therapy has the potential to fundamentally transform the treatment of chronic disease and age-related conditions.”

— Daniel Oliver, CEO & Co-Founder, Rejuvenate Bio 1

Sources

  1. Business Wire, “Rejuvenate Bio Announces $6 Million Financing and Strategic R&D Collaboration with Merck Animal Health,” June 8, 2026. Accessed June 2026. https://www.businesswire.com/news/home/20260602690569/en/Rejuvenate-Bio-Announces-$6-Million-Financing-and-Strategic-RD-Collaboration-with-Merck-Animal-Health↩↩↩↩↩

  2. citybiz, “Rejuvenate Bio Raises $6 Million and Partners With Merck Animal Health on Gene Therapy Development,” June 8, 2026. Accessed June 2026. https://www.citybiz.co/article/856883/rejuvenate-bio-raises-6-million-and-partners-with-merck-animal-health-on-gene-therapy-development/↩↩

  3. Yahoo Finance, “Rejuvenate Bio Announces $6 Million Financing and Strategic R&D Collaboration with Merck Animal Health,” June 8, 2026. Accessed June 2026. https://finance.yahoo.com/sectors/healthcare/articles/rejuvenate-bio-announces-6-million-120000417.html↩